Pfizer Global Medical Grants (GMG)Multidisciplinary Team Education in Duchenne Muscular Dystrophy (DMD) RFP
Academic Unit: inquire with unit
Memorial Deadline: Tuesday 19th, September 2023
External Deadline: Tuesday 26th, September 2023
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.
Date RFP Issued: August 17, 2023
Geographic Scope: US, Canada, Europe, South Korea, Japan, China, New Zealand, and Australia
Clinical Area: Duchenne Muscular Dystrophy (DMD)
Link to full RFP: Multidisciplinary Team Education in Duchenne Muscular Dystrophy (DMD)
Application Due Date: September 26, 2023
Specific Area of Interest: Projects that will be considered for Pfizer support will focus on:
- – Improving the medical and scientific understanding of DMD to help upskill and optimize multidisciplinary teams for the referral, diagnosis, treatment, and management of eligible patients
- – Addressing the holistic challenges that DMD presents to multidisciplinary teams
- – Addressing challenges in managing, monitoring, and caring for patients throughout their patient journey during an era of increased telehealth utilization and digital initiatives, including continuity of care, appropriate diagnoses, and support for patient referrals
- – Addressing the need for upskilling of both treatment and referral centers to ensure standardization of patient treatment, continuity of care, and follow-up
- – Identifying and addressing barriers that contribute to geographic, gender, and racial healthcare disparities disproportionately impacting patients with a rare disease in order to increase earlier diagnosis and treatment